MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease
暂无分享,去创建一个
G. Morgan | W. Gregory | M. Drayson | F. Ross | F. Davies | G. Cook | G. Jackson | A. Szubert | J. Child | R. Owen | S. Bell | G. Jackson